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hypertension should keep the portocaval gradient or HVPG as
primary end point and gold standard.
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Letters to the EditorA case of drug rash with eosinophilia and systemic symptoms (DRESS)
induced by telaprevir associated with HHV-6 active infectionTo the Editor: sis (F-2 stage, measured by ultrasonographic elastography),
We read with interest the article by Samain and colleagues [1] on
the ‘‘First case of drug rash eosinophilia and systemic symptoms
due to boceprevir’’ and would like to report herein the ﬁrst case
of the same syndrome, following telaprevir treatment in associa-
tion with HHV-6 active infection in skin tissue.
DRESS is a severe adverse drug-induced reaction that mani-
fests as a diffuse maculo-papular skin rash with fever, haemato-
logical abnormalities (leukocytosis, eosinophilia and/or atypical
lymphocytosis) and multi-organ involvement, especially liver
dysfunction [2]. The exact pathogenesis of the syndrome remains
largely unknown but recently it has been associated with a T cell
immune response directed towards herpes virus antigens and/or
the culprit drug along with HHV-6 reactivation [3,4]. DRESS
patients appear to possess low numbers of plasmacytoid den-
dritic cells, a leukocyte subset producing large amount of IFN-a
and specialized in antiviral responses, allowing reactivation of
HHVs (like HHV-6) [4]. Therefore, telaprevir as a culprit drug
may trigger viral reactivations that induce a pathogenetic antivi-
ral CD8+ immune response [2].
Moreover, HHV-6 reactivation has been linked with a more
severe course of DRESS [4]. In a previously described case of tela-
previr-induced DRESS, HHV-6 infection was documented only
indirectly by a serological analysis (simply measuring elevation
of the anti-HHV-6 antibody titre) [5] and not in the plasma and
skin tissue, as it was detected in our patient. Sixteen other cases
of DRESS (3 deﬁnite, 5 probable and 8 possible) induced by tela-
previr [6–8] have been described from 2010 to date, but all with-
out mentioning HHV-6 reactivation.
A 51-year-old Caucasian woman with chronic genotype 1a
hepatitis C (viral load 1.8  106 IU/ml), complicated with ﬁbro-
received treatment with the combination of interferon alfa-2a
(PegIFN) and ribavirin (RBV) for four weeks, without adverse
effect. Then telaprevir was added (2250 mg/daily) on April
2013 (day 0) in the absence of skin lesions. After three weeks
(day 24) from the telaprevir introduction, undetectable plasma
viraemia for HCV-ribonucleic acid (RNA) occurred and skin
manifestations as maculo-papular itchy lesions appeared on
the patient’s limbs. Oral antihistamines and topical steroids
were started with partial beneﬁt but after a few days the
patient worsened. Two weeks later, physical examination
revealed a diffuse maculo-papular exanthem, oro-pharyngeal
mucosa hyperaemia and bilateral painful axillar lymphadenopa-
thies associated with pruritus, fever (38 C), malaise and
arthralgia. Telaprevir was discontinued and oral prednisone
(0.5 mg/kg/daily) was promptly started. Cutaneous and systemic
symptoms improved in a few days, whereas the blood cells
count returned to normal within two weeks. Prednisone was
gradually decreased and stopped in one month.
Laboratory ﬁndings showed eosinophilia (white blood cell
count 5.10  109/L; eosinophils 19.8%, up to 1  109 cells/L) and
lymphocytopenia (7.2%, up to 0.40  109 cells/L). Antibodies
against cytomegalovirus (CMV), Epstein-Barr virus (EBV), and
adenovirus were indicative of past infection. Bacterial and fungal
culture of throat swab revealed a normal pharyngeal ﬂora.
Plasma HCV-RNA was persistently negative. Reactivation of
HHV-6 was demonstrated by detection of HHV-6 cell-free serum
viraemia (260 genome equivalents per ml). Anti-HHV-6 IgG
antibodies proved positive (titre 1/80), while anti-HHV-6 IgM
and anti-human herpes virus 7 (HHV-7) IgG and IgM antibodies
were negative. Active HHV-6 infection was demonstrated also
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Fig. 1. Detection and localization of HHV-6 in skin lesions by an antibody
panel including HHV-6 gp60/110 envelope glycoprotein, CD68, CD20, and CD3.
Immunohistochemical analysis of skin tissue (streptavidin-biotin-peroxidase)
showed: (A) HHV-6 gp60/110 envelope glycoprotein positivity (original
magniﬁcation 63), (B) CD68 positivity (original magniﬁcations 40), (C) CD3
positivity (original magniﬁcations 40) and (D) CD20 negativity (original
magniﬁcation 20). (This ﬁgure appears in colour on the web.)
JOURNAL OF HEPATOLOGYin the skin tissue both by quantitative real-time polymerase
chain reaction (qPCR) assay (3600 genome equivalents/10,000
cells) and immunohistochemical analysis with antibodies against
HHV-6 envelope glycoproteins (gp60/110 kDa) (Fig. 1A). Immu-
nohistochemical stainings revealed that HHV-6 infected cells
were positive for CD68, unequivocal marker of macrophages
(Langerhans cells) (Fig. 1B); conversely, they were negative for
CD3 and CD20 immunostaining (Fig. 1C and D). Histopathologica
examination of a cutaneous biopsy showed dermal perivascular
inﬂammatory inﬁltrate, composed of lymphocytes and histio-
cytes with scattered eosinophils in the dermis, consistent with
a drug reaction. Diagnosis of DRESS was conﬁrmed by the
presence of all seven diagnostic criteria, established in 2006 by
the Japanese Research Committee on Severe Cutaneous Adverse
Drug Reaction (J-SCAR): maculo-papular skin rash, developing
at least 3 weeks after starting therapy, with a limited number
of drugs, prolonged clinical symptoms after discontinuation of
the causative drug, lymphadenopathy, fever (>38 C), leukocyte
abnormalities (leukocytosis, atypical lymphocytosis, eosinophilia)
liver abnormalities, HHV-6 reactivation [9].
In order to decrease the rate of severe drug reactions in HCV
patients receiving new anti-HCV drugs, a rash management
plan has been developed: only in cases of a generalized rash
(involving more than 50% of the body surface area) and in
life-threatening or systemic reactions (like DRESS), telaprevir
must be immediately stopped and systemic corticosteroid
treatment is required [10].
In conclusion, we report, to our knowledge, the ﬁrst case of
telaprevir-induced DRESS associated with HHV-6 reactivation:
active HHV-6 infection was also documented in some skin
tissue resident macrophages (Langerhans cells). We also empha-
size the increased risk for DRESS in telaprevir-treated patients
that requires particular vigilance for the unpredictable and
potentially life-threatening evolution of this syndrome.
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